Doctor of Osteopathy Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

William Carpenter

Psychiatry Columbia, MO Doctor of Osteopathy

NPI 1164787594 CMS profile 710270

One Hospital Drive, Dc067.00, Columbia, MO 65212

Open in the dashboard

General payments

$2,529

174 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, William Carpenter of Columbia, MO is reported in the CMS Open Payments database as having received $2,529 across 174 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $388 23
2022 General $424 28
2021 General $773 58
2020 General $551 38
2019 General $394 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Carpenter
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to William Carpenter were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year William Carpenter Psychiatry median Middle half National median
2019 $394 $184 $59–$605 $163
2020 $551 $119 $36–$372 $114
2021 $773 $143 $43–$576 $132
2022 $424 $153 $50–$590 $149
2023 $388 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Lundbeck LLC $360 27 payments
  2. Otsuka America Pharmaceutical, Inc. $326 19 payments
  3. AbbVie, Inc. $299 25 payments
  4. Neurocrine Biosciences, Inc. $295 17 payments
  5. Janssen Pharmaceuticals, Inc $235 16 payments
  6. ITI, Inc. $152 10 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $139 11 payments
  8. Eisai Inc. $118 8 payments
  9. Teva Pharmaceuticals USA, Inc. $104 8 payments
  10. Alkermes, Inc. $73 5 payments
  11. Other $426 28 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $2,508 171 payments
  2. Education $21 3 payments
Products named General payments · program years 2019–2023
  1. VRAYLAR $299 25 payments
  2. REXULTI Psychiatry $284 16 payments
  3. BRINTELLIX $204 16 payments
  4. SPRAVATO $184 13 payments
  5. ABILIFY MAINTENA $168 10 payments
  6. REXULTI Psychiatry $157 11 payments
  7. CAPLYTA $152 10 payments
  8. INVEGA SUSTENNA $133 9 payments
  9. Dayvigo $118 8 payments
  10. INGREZZA $107 5 payments
  11. Other $1,293 90 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 55 drugs

Part D claims

3,812

Median for Psychiatry: 574

Drug cost

$383,545

Median for Psychiatry: $27,624

Branded share of claims

22.7%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 67 $90,594
Invega Sustenna Paliperidone Palmitate Brand 29 $71,147
Rexulti Brexpiprazole Brand 33 $55,367
Trintellix Vortioxetine Hydrobromide Brand 52 $30,180
Caplyta Lumateperone Tosylate Brand 13 $24,870
Uzedy Risperidone Brand 13 $17,871
Vyvanse Lisdexamfetamine Dimesylate Brand 29 $11,632
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 135 $8,605
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 71 $8,271
Clozapine Odt Clozapine Brand 13 $5,512

The 10 drugs with the highest cost, of 55 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$23,764

Medicare's payments for the services billed

Medicare patients

96

Average age 67

Services billed

336

62 women, 34 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 75%
High blood pressure 73%
Arthritis 54%
Diabetes 27%
Chronic kidney disease 23%
COPD 22%
Ischemic heart disease 21%
Atrial fibrillation 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

174 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record